ARS Pharmaceuticals, Inc.(SPRY)

Biotechnology · San Diego, CA

$4.28-0.01 (-0.35%)

Delayed quote: Oct 6, 2026, 2:40 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T18:43:16.902Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:43:16.902Z.

Quote observation: 2026-10-06T18:40:07.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 424,521,445
Total debt · period ending 2026-06-30: 171,603,000
Cash · period ending 2026-06-30: 8,163,000
TTM operating EBITDA · period ending 2026-06-30: -212,685,000

FMP input reference: 245dd754b0f03b0474a1f4d6c5429d137941524b53a54e0755d3e87780725df6

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SPRY EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

SPRY Competitors' EV/EBITDA Ratio

SPRY

ARS Pharmaceuticals, Inc.

Current

Market Cap

$424.52M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRTA

Prothena Corporation plc

vs SPRY

Market Cap

$423.68M

EV/EBITDA Ratio

N/A

TTM Avg

16.39x

3Y Avg

16.39x

5Y Avg

16.39x

TLRY

Tilray Brands, Inc.

vs SPRY

Market Cap

$426.41M

EV/EBITDA Ratio

23.04x

TTM Avg

25.27x

3Y Avg

25.27x

5Y Avg

25.27x

NEO

NeoGenomics, Inc.

vs SPRY

Market Cap

$428.72M

EV/EBITDA Ratio

N/A

TTM Avg

74.72x

3Y Avg

37.71x

5Y Avg

26.88x

EDIT

Editas Medicine, Inc.

vs SPRY

Market Cap

$428.93M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MPLT

MapLight Therapeutics, Inc.

vs SPRY

Market Cap

$415.88M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SENS

Senseonics Holdings, Inc.

vs SPRY

Market Cap

$413.76M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EIKN

Eikon Therapeutics, Inc. Common Stock

vs SPRY

Market Cap

$413.71M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TECX

Tectonic Therapeutic, Inc.

vs SPRY

Market Cap

$436.54M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ASMB

Assembly Biosciences, Inc.

vs SPRY

Market Cap

$437.17M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
ARS Pharmaceuticals, Inc. (SPRY)	$424.52M	N/A	N/A	N/A	N/A
Prothena Corporation plc (PRTA)vs ›	$423.68M	N/A	16.39x	16.39x	16.39x
Tilray Brands, Inc. (TLRY)vs ›	$426.41M	23.04x	25.27x	25.27x	25.27x
NeoGenomics, Inc. (NEO)vs ›	$428.72M	N/A	74.72x	37.71x	26.88x
Editas Medicine, Inc. (EDIT)vs ›	$428.93M	N/A	N/A	N/A	N/A
MapLight Therapeutics, Inc. (MPLT)vs ›	$415.88M	N/A	N/A	N/A	N/A
Senseonics Holdings, Inc. (SENS)vs ›	$413.76M	N/A	N/A	N/A	N/A
Eikon Therapeutics, Inc. Common Stock (EIKN)vs ›	$413.71M	N/A	N/A	N/A	N/A
Tectonic Therapeutic, Inc. (TECX)vs ›	$436.54M	N/A	N/A	N/A	N/A
Assembly Biosciences, Inc. (ASMB)vs ›	$437.17M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics